GlassScriptPhysician profile
Ronald Hiliary Hyde
NPI 1861488389
$4,448.13
in general payments reported to CMS, 2019-2025
30 companies · $999 in 2025
The $999 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $189 · 2021: $626 · 2022: $751 · 2023: $611 · 2024: $754 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311 · Education: $53.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.53 |
| Education | $53.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $600.38 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $492.58 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $374.18 | 2019-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.00 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $317.38 | 2019-2025 | Vafseo |
| Vifor Pharma, INC. | $293.83 | 2019-2024 | Veltassa |
| Amgen INC. | $278.21 | 2019-2025 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $190.49 | 2021-2024 | Terlivaz |
| Horizon Therapeutics Plc | $188.74 | 2021-2023 | Krystexxa |
| Travere Therapeutics, INC. | $162.96 | 2022-2025 | |
| Glaxosmithkline, LLC. | $155.87 | 2021-2024 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $132.76 | 2022-2025 | |
| Vantive US Healthcare LLC | $128.34 | 2025 | |
| Baxter Healthcare | $123.64 | 2024 | |
| Ardelyx, INC. | $102.87 | 2024-2025 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $97.04 | 2022-2024 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $96.38 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $85.86 | 2021-2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $60.77 | 2022-2024 | Ultomiris |
| Daiichi Sankyo INC. | $39.33 | 2019 | |
| Merck Sharp & Dohme LLC | $29.86 | 2024 | Prevymis |
| Genentech USA, INC. | $29.12 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $22.72 | 2025 | Dojolvi |
| Shield Therapeutics INC | $21.52 | 2022 | |
| Novo Nordisk INC | $20.29 | 2024 | Rivfloza |
| Novartis Pharmaceuticals Corporation | $18.44 | 2025 | |
| Lilly USA, LLC | $18.22 | 2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $15.86 | 2019 | |
| Genzyme Corporation | $15.46 | 2019 | |
| Vanda Pharmaceuticals INC. | $14.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Hyde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.